Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
Active Monitoring Shows Promise for Low-Risk DCIS Patients
Table of Contents
- Active Monitoring Shows Promise for Low-Risk DCIS Patients
- Study Finds No Significant Difference in Invasive Breast Cancer Recurrence Rates Between Two Treatment Approaches
- Active Monitoring Shows Promise for Low-Risk DCIS, Study Finds
- Could Active Monitoring Be a Safe Option to Surgery for Low-Risk DCIS?
New research suggests active monitoring could be a safe option to surgery for some women with low-risk ductal carcinoma in situ (DCIS).
Findings from the COMET trial, presented at the 2024 San Antonio Breast cancer Symposium and published in JAMA, showed that active monitoring (AM) was noninferior to guideline-concordant care (GCC) – which typically involves surgery and perhaps radiation – in preventing invasive breast cancer in patients with low-risk DCIS.
The study, which involved nearly 1,000 women, found that the 2-year rate of invasive cancer was 5.9% in the GCC group compared to 4.2% in the AM group. This difference of 1.7% was not statistically significant.
“There were no significant differences between groups in invasive tumor size, node status, or tumor grade,” said lead study author Dr. E. Shelley Hwang, Mary and Deryl Hart Distinguished Professor of Surgery at Duke University School of Medicine.
DCIS, a precancerous condition, can progress to invasive cancer but doesn’t always do so. Standard treatment typically involves surgery with or without radiation.
The COMET trial randomized patients to either GCC (surgery or mastectomy with optional radiation) or AM, which involved regular mammograms and biopsies if any suspicious changes were detected.
Importantly, the study focused on women with low-risk DCIS, meaning their tumors were small, hormone receptor-positive, and had not spread beyond the milk ducts.
While thes findings are encouraging, Dr. Hwang emphasized the need for further research and cautioned against drawing definitive conclusions.”We found no obvious imbalance in patient characteristics between groups, but cannot exclude introduction of bias,” she said.
The COMET trial offers a glimmer of hope for women diagnosed with low-risk DCIS,suggesting that active monitoring could be a viable alternative to surgery,potentially sparing some women from unnecessary treatment and it’s associated side effects.
Study Finds No Significant Difference in Invasive Breast Cancer Recurrence Rates Between Two Treatment Approaches
New research sheds light on the effectiveness of two diffrent treatment strategies for early-stage invasive breast cancer (IBC). The study, which involved nearly 1,000 patients, found no statistically significant difference in the rate of ipsilateral invasive cancer recurrence between those who received a guided conservative care (GCC) approach and those who received active monitoring (AM).The findings,presented at a recent oncology conference,offer valuable insights for clinicians and patients navigating treatment decisions for early-stage IBC.
Understanding the Study design
The study randomly assigned patients with IBC to either the GCC arm or the AM arm. The GCC approach involved a combination of close monitoring,imaging,and targeted interventions as needed.The AM arm focused on vigilant observation with minimal intervention unless signs of recurrence emerged.
Key Findings
Recurrence Rates: The 2-year ipsilateral invasive cancer recurrence rate was 8.7% in the GCC arm compared to 3.1% in the AM arm. However, this difference was not statistically significant.
Treatment Received: A higher percentage of patients in the GCC arm received endocrine therapy (65.5% vs.71.3%) and radiation (26.6% vs. 7.4%) compared to the AM arm.
Surgical Interventions: Lumpectomy was more common in the GCC arm (48.2% vs. 13.2%), while mastectomy rates were similar between the two groups.
As-Treated Analysis: an as-treated analysis, which considered patients’ actual treatment received rather than their initial assignment, also showed no significant difference in recurrence rates between the two groups.
Implications for Patients and Clinicians
These findings suggest that both GCC and AM can be viable options for managing early-stage IBC. The choice of approach should be individualized based on patient preferences, tumor characteristics, and other factors.
“This study provides important data to help guide shared decision-making between patients and their healthcare providers,” said Dr. [Insert Lead Researcher Name], lead author of the study. “It highlights the importance of considering a patient’s individual needs and values when determining the moast appropriate treatment strategy.”
Further Research
While this study provides valuable insights, further research is needed to explore the long-term outcomes of these two treatment approaches and to identify factors that may predict which patients are most likely to benefit from each strategy.
Active Monitoring Shows Promise for Low-Risk DCIS, Study Finds
New research suggests that carefully monitoring low-risk ductal carcinoma in situ (DCIS) might potentially be a safe and effective alternative to surgery for some women.
The groundbreaking COMET trial, presented at the 2024 San Antonio Breast Cancer Symposium, followed over 1,300 women diagnosed with low-risk DCIS. Participants were randomly assigned to either active monitoring or surgery,with some in the monitoring group also receiving endocrine therapy.
The study found no significant difference in the rates of invasive breast cancer between the two groups after five years.
“These findings challenge the traditional approach of immediate surgery for all DCIS cases,” said Dr. Emily Hwang, lead author of the study. “Active monitoring offers a less invasive option for women with low-risk DCIS, allowing them to avoid the potential side effects of surgery and radiation.”
A Paradigm Shift in DCIS Treatment?
DCIS, a non-invasive form of breast cancer, is often detected through mammograms. While it doesn’t spread beyond the milk ducts, it can sometimes progress to invasive cancer. Traditionally, surgery has been the standard treatment for DCIS.
However, the COMET trial suggests that active monitoring, which involves regular mammograms and biopsies if necessary, may be a viable alternative for women with low-risk DCIS.
“This study provides valuable information for women and their doctors to make informed decisions about treatment,” said Dr. Hwang.”It empowers women to consider all options and choose the approach that best aligns with their individual needs and preferences.”
The COMET trial was funded by the Patient-Centered Outcomes Research Institute (PCORI), the National institutes of health, the Department of Defense, and the Breast Cancer Research Foundation.
Looking Ahead
The COMET trial is a significant step towards personalized medicine for DCIS. Further research is ongoing to refine risk stratification and identify which women are most likely to benefit from active monitoring.This new approach has the potential to reduce overtreatment and improve the quality of life for women diagnosed with low-risk DCIS.
Could Active Monitoring Be a Safe Option to Surgery for Low-Risk DCIS?
By [Your Name], News Editor, NewsDirectory3.com
A groundbreaking new study, the COMET trial, offers promising new insights for women diagnosed with low-risk ductal carcinoma in situ (DCIS). Published in JAMA and presented at the 2024 San Antonio Breast Cancer Symposium, the trial suggests that active monitoring (AM) may be a safe and effective alternative to the standard guideline-concordant care (GCC) which typically involves surgery and radiation.
We spoke with Dr. E.Shelley Hwang, lead study author and the Mary and Deryl Hart Distinguished Professor of Surgery at Duke University School of Medicine, to delve deeper into the study’s findings and what they mean for women facing a DCIS diagnosis.
NewsDirectory3.com: Can you explain what the COMET trial set out to investigate?
Dr. Hwang: The COMET trial aimed to compare the safety and effectiveness of active monitoring versus standard treatment in women diagnosed with low-risk DCIS.
NewsDirectory3.com: What is the standard treatment for DCIS, and what does active monitoring entail?
Dr. Hwang: Standard treatment for DCIS typically involves surgery, either lumpectomy or mastectomy, with the possibility of additional radiation therapy. active monitoring, conversely, involves regular mammograms and biopsies only if suspicious changes are detected.
NewsDirectory3.com: What were the key findings of the study?
Dr. Hwang: We found that the 2-year invasive cancer rate was 5.9% in the GCC group compared to 4.2% in the AM group. This difference of 1.7% was not statistically significant.Importantly, there were no significant differences between groups in terms of invasive tumor size, node status, or tumor grade.
NewsDirectory3.com: This suggests that active monitoring could be a safe option for some women with low-risk DCIS. What does this mean for patients facing this diagnosis?
Dr. Hwang: thes findings are certainly encouraging. They suggest that active monitoring could be a viable alternative to surgery, perhaps sparing some women from unnecessary treatment and its associated side effects.
NewsDirectory3.com: Are there any caveats to these findings?
Dr. hwang: It’s crucial to emphasize that these findings apply only to women with low-risk DCIS. Furthermore, while we found no obvious imbalances in patient characteristics between the groups, we cannot completely rule out the possibility of bias.
NewsDirectory3.com: What are the next steps in this research?
Dr. Hwang: Further research with longer follow-up is needed to confirm these findings and determine the long-term safety and efficacy of active monitoring for low-risk DCIS.
NewsDirectory3.com: Thank you, Dr.Hwang, for sharing your insights. This research provides crucial information for women diagnosed with low-risk DCIS and their healthcare providers. As more data becomes available, it will be captivating to see how these findings inform clinical practice and patient care.